Experimental Use Exemption Cases
1. Concept of Experimental Use Exemption (Overview)
The Experimental Use Exemption allows the use of a patented invention without the patentee’s consent when such use is solely for experimentation, research, or testing, and not for commercial exploitation.
Core Rationale:
Promotes scientific progress
Allows researchers to verify, improve, or understand patented inventions
Prevents patents from becoming absolute monopolies blocking innovation
However, courts strictly interpret this exemption, and commercial intent often defeats the defence.
2. United Kingdom Case Laws
Case 1: Monsanto Co. v. Stauffer Chemical Co. (1985)
Facts:
Monsanto owned a patent for a herbicide.
Stauffer conducted experiments on the herbicide to seek regulatory approval and to prepare for commercial launch once the patent expired.
Issue:
Whether experiments conducted with a view to commercial exploitation fall under experimental use exemption.
Judgment:
The House of Lords rejected the experimental use defence.
Reasoning:
Experiments were not for discovering new knowledge
They were commercially motivated, aimed at market entry
The exemption applies only when the experiment’s primary purpose is scientific inquiry
Principle Established:
Experiments directed toward commercial use or regulatory approval do not qualify as experimental use.
Case 2: Madey v. Duke University (US Federal Circuit, 2002)
Facts:
Professor Madey owned patents related to laser technology.
Duke University continued using the patented technology after Madey left the university.
Duke claimed research exemption since it was a non-profit educational institution.
Issue:
Does non-commercial academic research qualify for experimental use exemption?
Judgment:
The court rejected Duke’s defense.
Reasoning:
Research furthered Duke’s legitimate business objectives
Enhanced reputation, attracted funding and students
Even non-profit use can be commercial in nature
Principle Established:
Experimental use exemption is extremely narrow in the US and applies only to acts done “for amusement, curiosity, or philosophical inquiry.”
3. European Union Case Law
Case 3: Roche Products Ltd v. Bolar Pharmaceutical Co. (US, but globally influential)
Facts:
Bolar used Roche’s patented drug before patent expiry
Purpose was to obtain FDA approval so the generic could enter the market immediately after expiry
Issue:
Is regulatory testing experimental use?
Judgment:
The US Supreme Court ruled against Bolar.
Impact:
Sparked the creation of the “Bolar Exemption” in many jurisdictions (including EU and India)
Legal Legacy:
Legislatures stepped in to allow regulatory testing as an exception
Demonstrates how judicial rejection led to statutory reform
4. Indian Case Laws and Statutory Context
India explicitly recognizes experimental use under Section 47 and Section 107A of the Patents Act, 1970.
Case 4: Bayer Corporation v. Union of India (2014)
Facts:
Bayer held a patent for Sorafenib Tosylate, an anti-cancer drug.
Indian companies conducted tests and exported samples for regulatory approval.
Issue:
Whether exporting patented drugs for research violates patent rights.
Judgment:
The court upheld the Bolar Exemption under Section 107A.
Reasoning:
Regulatory approval is essential for public health
Experimental use includes making, using, selling, or importing for regulatory purposes
No commercial sale to the public occurred
Principle Established:
Experimental use exemption in India is broader and includes acts necessary for regulatory compliance.
Case 5: Roche v. Cipla (Delhi High Court, 2008)
Facts:
Roche sued Cipla for infringing its patent on Erlotinib.
Cipla argued its activities were protected under experimental use.
Issue:
Whether pre-launch testing amounts to infringement.
Judgment:
The court accepted that research and experimentation is protected, but mass production is not.
Reasoning:
Limited experimental use is allowed
Any commercial scale manufacture crosses the line into infringement
Principle Established:
Experimental use must be limited, controlled, and non-commercial.
Case 6: Merck Sharp & Dohme Corp. v. Integra Lifesciences (US Supreme Court, 2005)
Facts:
Integra used patented peptides for preclinical research
Merck funded the research for future drug development
Issue:
Does experimental use include preclinical research?
Judgment:
The Supreme Court ruled in favor of Merck.
Reasoning:
Preclinical experiments reasonably related to regulatory submission are protected
Research need not guarantee FDA submission to qualify
Principle Established:
Experimental use includes preclinical research reasonably related to regulatory approval.
5. Comparative Analysis
| Jurisdiction | Scope of Experimental Use |
|---|---|
| UK | Narrow; excludes commercial intent |
| USA | Extremely narrow judicially; broader statutorily |
| EU | Statutory recognition; allows regulatory testing |
| India | Broadest; explicitly includes export for research |
6. Key Takeaways
Pure research is protected; commercial exploitation is not
Courts examine intent, scale, and purpose
Regulatory testing is allowed only by statute
India adopts a pro-public-health approach
Universities and non-profits are not automatically exempt
RELATED Blog
comments